JORGE MANUEL MERCADO, M.D. Chest Diseases of Northwestern Pennsylvania 3580 Peach Street, Suite 103A Erie, PA Office:
|
|
- Berniece Horton
- 6 years ago
- Views:
Transcription
1 JORGE MANUEL MERCADO, M.D. Chest Diseases of Northwestern Pennsylvania 3580 Peach Street, Suite 103A Erie, PA Office: WORK EXPERIENCE March present Chest Diseases of Northwestern Pennsylvania Pulmonary, Critical care and Sleep Medicine Attending Physician July present April 2010 March 2011 August 2009 March 2011 St Vincent s Hospital Medical Director Medical Intensive Care Unit/Step Down Unit UPMC Horizon Director Pulmonary Department UPMC Horizon Primary Health Network Pulmonary, Critical Care and Sleep Medicine Attending Physician MEDICAL CERTIFICATION September 2006 ABIM Board Certified in Internal Medicine October 2009 ABIM Board Certified in Pulmonary Medicine September 2011 ABIM Board Certified in Critical Care Medicine MEDICAL TRAINING July 2006-June 2009 Drexel University College of Medicine Pulmonary/Critical Care/Sleep Fellowship Program July 2003-July 2006 University of Pittsburgh - UPMC Presbyterian-Shadyside Hospital Internal Medicine Residency Program University of Buenos Aires, School of Medicine Medical Doctor M.D. AWARDS November 2005 American College of Physicians (ACP) Pennsylvania Chapter of Medicine Best Research Award Certificate of Merit November 2004 American College of Physicians (ACP) Pennsylvania Chapter of Medicine
2 Best Research Award Certificate of Merit May 2004 University of Pittsburgh Annual Research Award of the Department of Internal Medicine June 2004 University of Pittsburgh Intern of the year RESEARCH ACTIVITIES Molecular Biology and Genetics in Pulmonary Arterial Hypertension Peter Jones, PhD University of Pennsylvania 2006 July 2007 Controlled randomized single-blinded clinical trial using Angiotech central venous catheters (CVC) to prevent bacterial colonization on short term CVC Drexel University College of Medicine (Sub-investigator) Phase IV randomized double-blinded clinical trial comparing clinical efficacy of linezolid to vancomycin in the treatment of nosocomial pneumonia. Drexel University College of Medicine A 52 week, Randomized, Double Blind, Parallel Group Study Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma Drexel University College of Medicine Phase II pivotal multicenter multinational randomized double blinded placebo controlled study to evaluate the efficacy of TAK 242 in adults with severe sepsis. Drexel University College of Medicine Sept-Nov 2004 Molecular Biology and Genetics in Idiopathic Pulmonary Fibrosis (IPF) and Adult Respiratory Distress Syndrome (ARDS) Augustine Choi, M.D., Department of Pulmonary/Critical Care University of Pittsburgh April-July 2001 Clinical Research in Adult Respiratory Distress Syndrome Javier Aduen, M.D., Department of Pulmonary/Critical Care Mayo Clinic Jacksonville 1998 Research Assistant in neurotropic viruses J. Berria, M.D. Department of Microbiology University of Buenos Aires
3 A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease: DB A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating The Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo for 24- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD): LAC-MD-31. A Long-Term, Randomized, Study of the Safety and Tolerability of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol Fumarate compared with Formoterol Fumarate in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD): LAC-MD-32. A 52-week, double-blind, randomized, placebo controlled parallel group study to evaluate the effect of roflumilast 500 μg on exacerbations in severe to very severe COPD patients treated with fixed dose combination LABA/ICS (Advair 250/50 μg or, Symbicort 160/4.5 μg): ROF-MD-07. A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or an increased risk for cardiovascular disease: HZC SUMMIT. Novartis Pharmaceuticals trial entitled: A randomized, placebocontrolled, dose-ranging, multi-centre trial of QAW039 (1-450 mg p.o.) to investigate the effect on FEV 1 in and ACQ patients with moderate-to-severe, persistent, allergic asthma, inadequately controlled with ICS therapy: CQAW039A2206. A Phase III, Long-Term, Randomized, Double-Blind, Extension Study of the Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients with Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD): LAC-MD-36. A randomized, double blind, parallel group study to assess the efficacy and safety of 12 weeks of once daily, orally inhaled, coadministration of olodaterol 5µg (delivered by the Respimat Inhaler) and tiotropium 18µg (delivered by the HandiHaler ) compared to once daily, orally inhaled, co-administration of placebo (delivered by the Respimat Inhaler) and tiotropium 18µg (delivered by the HandiHaler ) in patients with Chronic Obstructive Pulmonary Disease (COPD):
4 PUBLICATIONS Jorge M. Mercado MD, Lawrence McDermott, MD. Drexel University College of Medicine, Philadelphia, Pennsylvania. TNF DIRECTED APPROACHES FOR RESPIRATORY DISEASES Hansel et al. New drugs and targets for Respiratory diseases. Prous Science. UNDER REVISION Jorge M. Mercado MD, D. Michael Elnicki MD, Phillip Olhaussen, MD, Yoshiko Ogawa, MD, Alessandro Rinaldo, PhD; Asher Tulsky MD. University of Pittsburgh, Pittsburgh; Norwalk Hospital, Norwalk; Beth Israel Medical Center, New York. NIGHTFLOAT FACTS DATA RECOLLECTION OF A NIGHTFLOAT ROTATION UNDER REVISION EFFECTS OF INTRAOPERATIVE FLUID IN THE DEVELOPMENT OF EARLY PULMONARY EDEMA AFTER LIVER TRANSPLANTATION. Javier Aduen, MD; Wolff Stapelfeldt, MD; Charles Burger, MD; Howard Jolles, MD; Jorge Mercado, MD; Stephen Grinton, MD; Gavin Divertie, MD and Margaret Johnson, MD. Pulmonary and Critical Medicne. Mayo Clinic, Jacksonville, Florida; Anesthesiology, Mayo Clinic, Jacksonville, Florida; Radiology, Mayo Clinic, Jacksonville, Florida and Anesthesiology and Critical Care, Mayo Clinic, Jacksonville, Florida. CHEST, October 2002 SUPPLEMENT. Page 113S. PULMONARY ARTERIAL HYPERTENSION AND ITS RELATIONSHIP WITH EARLY PULMONARY EDEMA AFTER LIVER TRANSPLANTATION Javier Aduen, MD; Wolff Stapelfeldt, MD; Margaret Johnson, MD; Jorge Mercado, MD; Stephen Grinton, MD; Gavin Divertie, MD and Charles Burger, MD. Pulmonary and Critical Care Medicine, Mayo Clinic, Jacksonville, Florida; Anesthesiology, Mayo Clinic, Jacksonville, Florida and Anesthesiology and Critical Care, Mayo Clinic, Jacksonville, Florida. CHEST, October 2002 SUPPLEMENT. Page 113S-114S ORAL PRESENTATIONS & POSTERS June 2008 The Laennec Society of Philadelphia A twist of Lyme, Mercado JM Oral Presentation November 2005 American College of Physicians (ACP), Pennsylvania Chapter of Internal Medicine An Uncommon Complication of Chronic Obstructive Pulmonary Disease Mercado, JM, Muddana V, Javed, A, Cooper, A. Variables Associated with Complications from Gastrointestinal Endoscopic Procedures Muddana, V, Mercado, JM, Arnold, G. Development of an Insulin Sliding Scale Protocol Night Float Study Mercado, JM, Cooper, A
5 May 2005 November 2004 American Thoracic Society, International Conference San Diego, CA Evaluation of Plasma Cytokines in ALI/ARDS and Septic Patients Sethi, JM, Mercado, JM, Lucht, LA, Donahoe, M, Choi, AMK, and Zhang, Y ACP Pennsylvania Chapter of Internal Medicine Nightfloat An intern s experience Mercado J.M., MD; Tulsky A., MD May 2004 March 2004 Society of General Internal Medicine (SGIM), National Meeting Chicago, IL Night float An intern s experience Mercado J.M., MD; Tulsky A., MD SGIM Mid-Atlantic Regional Meeting Philadelphia, PA Night float An intern s experience Mercado J.M., MD; Tulsky A., MD Proton Pump inhibitors induced thrombocytopenia Mercado J.M., MD; Tulsky A., MD 6-Thioguanine induced nodular regenerative hyperplasia in a patient with ulcerative colitis and normal liver function tests Mercado J.M., MD; Arnold G., MD US MEDICAL ELECTIVES 2001 The William J. Harrington Training Program for Latin America University of Miami Pediatric Cardiology, Trauma Surgical ICU, Internal Medicine Mayo Clinic, Jacksonville Campus Cardiovascular Diseases Service Wards and Echo lab, Pulmonary Service MICU and Research MEMBERSHIPS SCCM (Society of Critical Care Medicine) ACCP (American College of Chest Physicians) ATS (American Thoracic Society) ACP (American College of Physicians) SGIM (Society General Internal Medicine) AMA (American Medical Association)
6 COMMUNITY SERVICES Birmingham Clinic Medical attention to underserved population of South 2004 Pittsburgh, PA 1997 Buenos Aires City Health Department Lectures on HIV prevention to high school students and community on behalf of the Ministry of Health 1997 Vaccination Campaign to underserved population of Buenos Aires, Argentina TEACHING EXPERIENCE 2009 Present Pulmonary and Critical Care Lectures to Residents and LECOM medical students UPMC Horizon Pulmonary and Critical care Lectures to DUCOM medical students Drexel University College of Medicine (DUCOM) Teaching Assistant, University of Buenos Aires Virology Renal Physiology Clinical Pharmacology ADDITIONAL INFORMATION Interests Fluent in Spanish, English, Italian Basic knowledge of Portuguese, German Hobbies include literature, impressionist painting, music, opera, and sports Revised 1/13
Joseph E. Rowane, D.O. Home Address: 6073 Volkman Road Erie, PA 16506
Joseph E. Rowane, D.O. Home Address: 6073 Volkman Road Erie, PA 16506 Professional Address: Chest Diseases of Northwestern PA 3580 Peach Street--Suite 103 Erie, Pennsylvania 16508 Phone: (814) 864-4755
More informationCURRICULUM VITAE KENNETH D. CHINSKY, M.D.
KENNETH D. CHINSKY, M.D. Chest Diseases of Northwestern PA 3580 Peach Street, Suite 103A Erie, PA 16508 www.chestdiseases.yourmd.com Phone: (814) 864-4755 FAX: (814) 864-5430 Email: Sigsbee@aol.com Home
More informationCURRICULUM VITAE GREGORY JAMES FERREIRA M.D., FCCP
CURRICULUM VITAE GREGORY JAMES FERREIRA M.D., FCCP Business address: Hautamaki & Horiuchi Personal Physicians of Sarasota 1843 Floyd Street Sarasota, Fl Phone: 941.951.3920 Fax: 941.951.3922 Prior business
More informationJeffrey P. McGovern, MD, FCCP, ABSM
Jeffrey P. McGovern, MD, FCCP, ABSM 3580 Peach Street--Suite 103A Erie, PA 16508 814-864-4755 (Home: 814-868-1155) Date of Birth: March 10, 1960 Spouse: Kathleen Medical Licenses:, Pennsylvania MD047962L
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationCURRICULUM VITAE TODD KEN HORIUCHI, M.D., FCCP
CURRICULUM VITAE TODD KEN HORIUCHI, M.D., FCCP Present Business Address: Prior Business Address: Hautamaki & Horiuchi Personal Physicians of Sarasota 1843 Floyd Street Sarasota, FL 34239 Telephone: 941-951-3920
More informationCSRC COPD Initiative Think Tank meeting Washington DC March 6, 2014
What is the role of outcome studies in pulmonary drug development and what data can be collected during development to sufficiently characterize an agent so that an outcome study not necessary? CSRC COPD
More informationTest Your Inhaler Knowledge
A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary
More informationCURRICULUM VITAE TODD KEN HORIUCHI, M.D., FCCP
CURRICULUM VITAE TODD KEN HORIUCHI, M.D., FCCP Present Business Address: Prior Business Address: Hautamaki & Horiuchi Personal Physicians of Sarasota 1843 Floyd Street Sarasota, FL 34239 Telephone: 941-951-3920
More informationRobert J. Cooper, M.D., F.A.C.E., F.A.C.P. 20 Cherry Lane Longmeadow, MA Phone: (413) Fax: (413)
Robert J. Cooper, M.D., F.A.C.E., F.A.C.P. 20 Cherry Lane Longmeadow, MA 01106 Phone: (413) 387-5971 Fax: (413) 567-3950 ShaRobCoop@aol.com PROFESSIONAL EXPERIENCE: New England Endocrine & Thyroid Center,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationCurriculum Vitae, Ward Jackson Paine, M.D. Ward Jackson Paine, M.D. Exemplar Research, Inc Mileground Road Morgantown, WV 26505
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Ward Jackson Paine,
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationRonald H. Saff, M.D. Curriculum Vitae
Ronald H. Saff, M.D. Curriculum Vitae Address 2300 Centerville Road Tallahassee, FL 32308 (850) 766-7886 ronsaff@aol.com Certification Board Certified Internal Medicine, September 1992 Board Certified
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationSUBURBAN LUNG ASSOCIATES, S.C. 800 Biesterfield Road, Suite 510 Elk Grove Village, IL 60007
SUBURBAN LUNG ASSOCIATES, S.C. 800 Biesterfield Road, Suite 510 Elk Grove Village, IL 60007 NAME...EDWARD J. DIAMOND MD, FCCP, MBA PROFESSIONAL EMPLOYMENT..President Suburban Lung Associates, S.C. Elk
More informationSelect Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationPharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08
Pharmacological Management of Obstructive Airways in Humans Introduction to Scientific Research Submitted: 12/4/08 Introduction: Obstructive airways can be characterized as inflammation or structural changes
More informationQUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)
Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationKashif Raza. Jul Jun Govt. Zamindar Degree College, FSc. Certificate Bio, Phys, Chem Gujrat, Pakistan GRADUATE:
Kashif Raza Education and Training UNDERGRADUATE: Jul. 1989 Jun. 1991 Govt. Zamindar Degree College, FSc. Certificate Bio, Phys, Chem Gujrat, Pakistan. 1991 GRADUATE: Sep.1991- Aug. 1997 Nishtar Medical
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationNew and Novel Medications for Respiratory Care
New and Novel Medications for Respiratory Care JASON MOORE, PHARM.D. BCCCP CLINICAL STAFF PHARMACIST STORMONT-VAIL HEALTH Objectives Quick overview of the newest FDA-approved repiratory-related medications
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationChronic obstructive pulmonary disease (COPD) is characterized
DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationYear in review. Vit Perlik Director of Regulatory Science and Clinical Development
Year in review Vit Perlik Director of Regulatory Science and Clinical Development Content Year in review Covering September 2013 to September 2014 Where the regulation goes selection of events for illustration
More informationSupplementary materials
Supplementary materials Table S1 Patient comorbidities by diagnosis Total Asthma n (%) 5348 (148.4) COPD n (%) 4563 (143.4) ACOS n (%) 469 (197.9) No other comorbidities 95 (26.4) 614 (19.3) 27 (11.4)
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationDrug Effectiveness Review Project Summary Report
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPulmonary and Critical Care Year in Review
Pulmonary and Critical Care Year in Review Heath E Latham, MD Assistant Professor University of Kansas Dept of Internal Medicine Division of Pulmonary and Critical Care None Disclosure Lung Cancer Screening
More informationNot available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone
More informationSUBURBAN LUNG ASSOCIATES, S.C. 800 Biesterfield Road, Suite 510 Elk Grove Village, IL 60007
SUBURBAN LUNG ASSOCIATES, S.C. 800 Biesterfield Road, Suite 510 Elk Grove Village, IL 60007 NAME...ROBERT W. HART MD, FCCP OFFICE ADDRESS... 800 Biesterfield Road, Ste 510 Elk Grove Village, Il. 60007
More informationStudy No.: SFCA3007 Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS
Study No.: A3007 Title: A Randomized, Double-Blind, -Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate
More informationAnaesthesia-R3 & R4, Queen's University - including a 3 month rotation in children's anaesthesia at CHEO
CURRICULUM VITAE NAME: OFFICE: PLACE OF BIRTH: CITIZENSHIP: LANGUAGE: HOBBIES AND INTERESTS: Charles Bryant CATTRAN University of Ottawa Heart Institute 40 Ruskin Street, H2410 Ottawa, Ontario K1Y 4W7
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCombination Beta2-Agonist/Corticosteroid Inhalers
Combination Beta2-Agonist/Corticosteroid Inhalers Policy Number: 5.01.572 Last Review: 7/2017 Origination: 6/2014 Next Review: 7/2018 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationreslizumab (Cinqair )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationAdam Webb Page 1 EMORY UNIVERSITY SCHOOL OF MEDICINE STANDARD CURRICULUM VITAE FORMAT
Adam Webb Page 1 EMORY UNIVERSITY SCHOOL OF MEDICINE STANDARD CURRICULUM VITAE FORMAT Revised: 04/01/12 1. Name: Adam Christopher Webb 2. Current Titles and Affiliations: a. Academic appointments: 1. Primary
More informationInterQual Level of Care 2018 Index
InterQual Level of Care 2018 Index Long-Term Acute Care (LTAC) Criteria The Index is an alphabetical listing of conditions and/or diagnoses designed to guide the user to the criteria subset where a specific
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationThree better than 1 or 2?
Three better than 1 or 2? DISCLOSURE Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance of NS. (DEANS). DEU prepares Drug Evaluation Reports for the Atlantic
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationBack to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill
Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill Joe Palumbo PGY-2 Critical Care Pharmacy Resident Buffalo General Medical Center Disclosures
More informationCURRICULUM VITAE FRANCIS J. AVERILL, M.D., J.D. Pulmonary, Critical Care, Sleep Disorders, Allergy & Immunology. Medical Doctor (M.D.
CURRICULUM VITAE FRANCIS J. AVERILL, M.D., J.D. Pulmonary, Critical Care, Sleep Disorders, Allergy & Immunology PRIMARY OFFICE ADDRESS: St. Francis Sleep Allergy & Lung Institute 802 N. Belcher Road Clearwater,
More informationCurriculum Vitae, Joseph J. Savon, M.D.
CONTACT INFORMATION: Joseph J. Savon, M.D. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationDose. Route. Units. Given. Dose. Route. Units. Given
Chapter 4 Respiratory Andrew Stanton SALBUTAMOL (in acute asthma) 5 in acute asthma Nebulised (driven by oxygen not air) 4 6 hourly In acute severe asthma not responding to initial treatment or in life-threatening
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationumeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline
umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline 04 July 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationATS 2013 International Conference May Philadelphia Pennsylvania
American Journal of Respiratory and Critical Care Medicine American Journal of Respiratory Cell and Molecular Biology Proceedings of the American Thoracic Society STEPHEN C. CRANE, PhD, MPH Executive Director
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationAclidinium bromide/formoterol Endpoint category. RR Endpoint. [95% CI 2 ] Study. with event
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationCombination Beta2-Agonist/Corticosteroid Inhalers Policy Number: Last Review: Origination: Next Review: Policy When Policy Topic is covered:
Combina ation Beta2-Agonist/Corticosteroid Inhalers Policy Number: 5.01.572 Origination: 06/2014 Last Review: 07/2014 Next Review: 07/2015 Policy BCBSKC will provide coverage for the combination beta2-agonist/corticosteroid
More informationCurriculum Vitae Carlos Emilio Picone, M.D., FACP, FCCP 5530 Wisconsin Ave. Suite 930 Chevy Chase, MD
Curriculum Vitae Carlos Emilio Picone, M.D., FACP, FCCP 5530 Wisconsin Ave. Suite 930 Chevy Chase, MD 20815 cpicone@chevychasepulmonary.com Personal Information: Date of Birth: March 10, 1966 Place of
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationMUHAMMAD YASIN. Islamabad College for Boys G-6/3 Islamabad. Major: Physics, Biology, and Chemistry 08/1997 to 08/1999
MUHAMMAD YASIN E-mail: dr.yasinmd@gmail.com Islamabad College for Boys G-6/3 Islamabad. Major: Physics, Biology, and Chemistry 08/1997 to 08/1999 Punjab University, Lahore, Pakistan 12/1999-09/2002 B.Sc.
More informationSpecific Basic Standards for Osteopathic Fellowship Training in Pulmonary / Critical Care Medicine
Specific Basic Standards for Osteopathic Fellowship Training in Pulmonary / Critical Care Medicine American Osteopathic Association and American College of Osteopathic Internists BOT Rev. 2/2011 These
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report January 2018 Drug umeclidinium bromide (Incruse Ellipta) Indication Listing request Dosage form(s) Manufacturer Indicated for long-term, once daily maintenance
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationRobert J. Cooper, M.D., F.A.C.E., F.A.C.P. 20 Cherry Lane Longmeadow, MA Phone: (413) Fax: (413)
Robert J. Cooper, M.D., F.A.C.E., F.A.C.P. 20 Cherry Lane Longmeadow, MA 01106 Phone: (413) 387-5971 Fax: (413) 567-3950 ShaRobCoop@aol.com PROFESSIONAL EXPERIENCE: Baystate Medical Center 3300 Main Street
More informationChronic Disease Management when Resources are Limited
Chronic Disease Management when Resources are Limited Paul R. Larson MD, MS, DIM&PH Director, Global Health Education UPMC St. Margaret Family Medicine Residency Pittsburgh, PA larsonpr@upmc.edu Disclosures
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationUpdate in Pulmonology Update in Medicine and Primary Care November 11, 2017
Update in Pulmonology Update in Medicine and Primary Care November 11, 2017 Denitza P. Blagev, MD Pulmonary & Critical Care Medicine Director, Schmidt Chest Clinic Director, Lung Cancer Screening Program
More informationTHE BEST I HAVE READ THIS YEAR (IN PULMONARY AND CRITICAL CARE)
23 March 2018 Boca Raton, Florida THE BEST I HAVE READ THIS YEAR (IN PULMONARY AND Johnson.margaret2@mayo.edu No disclosures or off label uses CRITICAL CARE) Margaret M. Johnson, MD Chair, Division of
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationCURRICULUM VITAE BIOGRAPHICAL. Business Phone: (412) Business Fax: (412) EDUCATION and TRAINING
Name: Lori E. Cherok, MS, RDN, LDN, CNSC CURRICULUM VITAE BIOGRAPHICAL Business Address: University of Pittsburgh 4042 Forbes Tower 15260 E-Mail Address: lcherok@pitt.edu Business Phone: (412) 383-6566
More informationUPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE Radhika Shah, MD Erlanger Health System University of Tennessee College of Medicine Chattanooga Respiratory, Critical Care, and Sleep medicine No disclosures
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN VI.1 Summary of risk management plan for RELVAR ELLIPTA (fluticasone furoate/vilanterol) This is a summary of the risk management plan (RMP) for RELVAR ELLIPTA.
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationCinqair (reslizumab injection for intravenous use)
Cinqair (reslizumab injection for intravenous use) Policy Number: 5.02.522 Last Review: 04/2018 Origination: 04/2016 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More information37 th Pulmonary WinterCourse Program Agenda
TARGET AUDIENCE: Practitioners of pulmonary medicine, thoracic surgery, thoracic oncology, chest radiology, thoracic pathology, physician assistants, advanced nurse practitioners, registered nurses and
More informationSafety of β2-agonists in asthma
Safety of β2-agonists in asthma Sanjeeva Dissanayake IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Overview Origin of concerns Mechanistic hypotheses Large scale clinical datasets Interpretation
More informationCOPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre
COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationRespiratory Inhalers. Identification Guide Version 3
Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More information